Vtv Therapeutics INC 8-K filings

vTv Therapeutics is moving forward with a Phase 3 trial for its drug cadisegliatin, aimed at improving blood sugar control in Type 1 diabetes patients, backed by a recent $51 million investment.

vTv Therapeutics has entered into a sales agreement for a potential $50 million at-the-market offering and reported a preliminary cash balance of $9.4 million as of December 31, 2023.

vTv Therapeutics has successfully completed a $51 million private placement with healthcare-focused investors to advance its Phase 3 trial for cadisegliatin in type 1 diabetes.